

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**Date of Report: July 25, 2025**  
(Date of earliest event reported)

---



**KIMBERLY-CLARK CORPORATION**  
(Exact name of registrant as specified in its charter)

---

**Delaware**

**1-225**

**39-0394230**

(State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification No.)

**P.O. Box 619100**  
**Dallas, TX**  
**75261-9100**  
**(Address of principal executive offices)**  
**(Zip code)**

**Registrant's telephone number, including area code: (972) 281-1200**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock-\$1.25 par value	KMB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

As previously disclosed, on June 5, 2025, Kimberly-Clark Corporation ("Kimberly-Clark" or the "Company") announced the entry into an agreement with Suzano S.A. ("Suzano") to form a joint venture to be comprised of substantially all the operations of the Company's former International Family Care and Professional ("IFP") segment (the "IFP Business"). At the time of closing, Suzano along with certain of its wholly-owned subsidiaries will acquire a 51% interest in the joint venture for a purchase price of approximately \$1.7 billion, subject to certain closing adjustments, and the Company will retain a 49% equity interest (the "IFP Transaction").

The Company determined the IFP Transaction represents a strategic shift that will have a major effect on its operations and financial results. As a result, effective in the second quarter of fiscal 2025, the results of the IFP Business are reported as discontinued operations in the Company's condensed consolidated financial statements.

To assist investors in comparing the Company's historical results, the Company is providing supplemental historical financial results reflecting the IFP Business as discontinued operations in Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

## (d) Exhibits.

99.1 [Supplemental Historical Financial Information, dated July 25, 2025](#)

- 101 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
- 104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KIMBERLY-CLARK CORPORATION

By: /s/ Andrew Scribner

Andrew Scribner

Vice President and Controller

Date: July 25, 2025

## SUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION

Unless the context otherwise requires, the terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.

### **Forward Looking Statements**

Certain matters contained in this supplemental information concerning the business outlook, including raw material, energy and other input costs, our plans and expectations regarding the pending IFP Transaction, the anticipated charges and savings from the 2024 Transformation Initiative, cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina and Türkiye, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark. There can be no assurance that these future events will occur as anticipated or that our results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them.

The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the achievement of future cost savings and projected volume increases. In addition, many factors outside our control, including risks and uncertainties around the pending IFP Transaction (including risks related to delays or failure to complete the proposed transaction, the incurrence of significant transaction and separation costs, adverse market reactions, regulatory or legal challenges, and operational disruptions), risks that we are not able to realize the anticipated benefits of the 2024 Transformation Initiative (including risks related to disruptions to our business or operations or related to any delays in implementation), war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), government trade or similar regulatory actions (including current and potential trade and tariff actions affecting the countries where we operate and the resulting negative impacts on our supply chain, commodity costs, and consumer spending), pandemics, epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, disruptions in the capital and credit markets, counterparty defaults (including customers, suppliers and financial institutions with which we do business), failure to realize the expected benefits or synergies from our acquisition and disposition activity, impairment of goodwill and intangible assets and our projections of operating results and other factors that may affect our impairment testing, changes in customer preferences, severe weather conditions, regional instabilities and hostilities (including the war in Israel), potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, could affect the realization of these estimates.

The factors described under Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K"), or in our other SEC filings, among others, could cause our future results to differ from those expressed in any forward-looking statements made by us or on our behalf. Other factors not presently known to us or that we presently consider immaterial could also affect our business operations and financial results.

### **Background**

On June 5, 2025, we announced that the Company will form a joint venture with Suzano S.A. ("Suzano") and Suzano International Holding B.V., a wholly-owned subsidiary of Suzano ("Buyer"), comprised of substantially all the operations of the Company's former International Family Care and Professional segment (the "IFP Business"). To facilitate this transaction, we entered into an Equity and Asset Purchase Agreement (the "Purchase Agreement") with Buyer, pursuant to which we will, among other things, effectuate a reorganization through the transfer of certain assets, liabilities and equity interests of the IFP Business to Kimberly-Clark IFP NewCo B.V., an indirect wholly-owned subsidiary of the Company (the "Joint Venture"). At the time of closing, which is expected to take place in mid-2026 and will only take place following the satisfaction of consultation requirements and customary closing conditions, including obtaining required regulatory approvals, Buyer will acquire a 51% interest in the Joint Venture for a purchase price of approximately \$1.7 billion, subject to certain closing adjustments set forth in the Purchase Agreement, and we will retain a 49% equity interest (the "IFP Transaction").

In accordance with ASC 205, *Presentation of Financial Statements*, we determined the IFP Transaction represents a strategic shift that will have a major effect on our operations and financial results. Accordingly, effective in the second quarter of fiscal 2025, the results of the IFP Business are reported as discontinued operations and excluded from both continuing operations and segment results for all reporting periods (including comparable historical periods).

#### *Segment Reporting*

As discussed above, the results of the IFP Business are excluded from segment results for all reporting periods (including comparable historical periods). This includes certain costs that were previously allocated to the International Personal Care ("IPC") segment that relate to assets or activities that are part of the IFP Transaction. These costs have been removed from the results of the IPC segment and are reported as discontinued operations.

Additionally, certain operations and commercial activities of the former IFP segment retained by the Company are now reported in the North America ("NA") and IPC segments.

As a result, the Company's continuing operations are now organized into two reportable segments defined by geographic region: North America and International Personal Care.

Further, Corporate and Other now includes the following:

- Operations of the former IFP segment that were divested prior to the IFP Transaction and therefore not reported as discontinued operations.
- Costs previously allocated to the former IFP segment that are not directly attributable to the operations nor included in the IFP Transaction and therefore are not reported as discontinued operations.

For informational purposes only, we have recast our historical financial and segment results to reflect the presentation of the IFP Business as discontinued operations for each of the quarters ended March 31, 2025, December 31, 2024, September 30, 2024, June 30, 2024, and March 31, 2024, and the years ended December 31, 2024 and December 31, 2023. These changes had no impact on our consolidated financial results for any of the periods presented in our Quarterly Reports on Form 10-Q for the respective interim periods outlined above, or any of the annual periods presented in our 2024 Form 10-K.

The following unaudited financial information is based on our historical consolidated financial statements after giving effect to the reporting of the IFP Business as discontinued operations. This supplemental information should be read together with our unaudited condensed consolidated financial statements and related notes in each of our Quarterly Reports on Form 10-Q for the respective interim periods outlined above, and our audited consolidated financial statements and related notes in our 2024 Form 10-K. The financial information contained in this supplemental information is not indicative of future or annual results.

**Kimberly-Clark Corporation and Subsidiaries**  
**Condensed Consolidated Statements of Income**  
**Recast to Present the IFP Business as Discontinued Operations**  
**(Unaudited)**

(In millions, except per share amounts)	Year Ended December 31	
	2024	2023
<b>Net Sales</b>	\$ 16,805	\$ 17,146
Cost of products sold	10,516	10,877
<b>Gross Profit</b>	6,289	6,269
Marketing, research and general expenses	3,930	3,615
Impairment of intangible assets	97	658
Other (income) and expense, net	(438)	68
<b>Operating Profit</b>	2,700	1,928
Nonoperating expense	(60)	(95)
Interest income	48	66
Interest expense	(270)	(293)
<b>Income from Continuing Operations Before Income Taxes and Equity Interests</b>	2,418	1,606
Provision for income taxes	(442)	(343)
<b>Income from Continuing Operations Before Equity Interests</b>	1,976	1,263
Share of net income of equity companies	216	196
<b>Income from Continuing Operations</b>	2,192	1,459
<b>Income from Discontinued Operations, Net of Income Taxes</b>	386	305
<b>Net Income</b>	2,578	1,764
Net income attributable to noncontrolling interests	(33)	—
<b>Net Income Attributable to Kimberly-Clark Corporation</b>	\$ 2,545	\$ 1,764
<b>Per Share Basis</b>		
<b>Net Income Attributable to Kimberly-Clark Corporation</b>		
<b>Basic:</b>		
Continuing operations	\$ 6.43	\$ 4.32
Discontinued operations	1.15	0.90
<b>Basic Earnings per Share</b>	\$ 7.58	\$ 5.22
<b>Diluted:</b>		
Continuing operations	\$ 6.41	\$ 4.31
Discontinued operations	1.14	0.90
<b>Diluted Earnings per Share</b>	\$ 7.55	\$ 5.21

**Kimberly-Clark Corporation and Subsidiaries**  
**Condensed Consolidated Statements of Income**  
**Recast to Present the IFP Business as Discontinued Operations**  
**(Unaudited)**

(In millions, except per share amounts)	Three Months Ended				
	March 31 2025	December 31 2024	September 30 2024	June 30 2024	March 31 2024
<b>Net Sales</b>	\$ 4,054	\$ 4,104	\$ 4,144	\$ 4,231	\$ 4,326
Cost of products sold	2,545	2,659	2,580	2,637	2,640
<b>Gross Profit</b>	1,509	1,445	1,564	1,594	1,686
Marketing, research and general expenses	855	1,006	1,006	967	951
Impairment of intangible assets	—	—	97	—	—
Other (income) and expense, net	23	19	(565)	88	20
<b>Operating Profit</b>	631	420	1,026	539	715
Nonoperating expense	(17)	(15)	(15)	(15)	(15)
Interest income	7	11	18	9	10
Interest expense	(64)	(64)	(67)	(72)	(67)
<b>Income from Continuing Operations Before Income Taxes and Equity Interests</b>	557	352	962	461	643
Provision for income taxes	(131)	(47)	(187)	(60)	(148)
<b>Income from Continuing Operations Before Equity Interests</b>	426	305	775	401	495
Share of net income of equity companies	44	44	48	63	61
<b>Income from Continuing Operations</b>	470	349	823	464	556
<b>Income from Discontinued Operations, Net of Income Taxes</b>	103	103	92	89	102
<b>Net Income</b>	573	452	915	553	658
Net income attributable to noncontrolling interests	(6)	(5)	(8)	(9)	(11)
<b>Net Income Attributable to Kimberly-Clark Corporation</b>	<u>\$ 567</u>	<u>\$ 447</u>	<u>\$ 907</u>	<u>\$ 544</u>	<u>\$ 647</u>
<b>Per Share Basis</b>					
<b>Net Income Attributable to Kimberly-Clark Corporation</b>					
<b>Basic:</b>					
Continuing operations	\$ 1.40	\$ 1.03	\$ 2.43	\$ 1.35	\$ 1.62
Discontinued operations	0.31	0.31	0.27	0.26	0.30
<b>Basic Earnings per Share</b>	<u>\$ 1.71</u>	<u>\$ 1.34</u>	<u>\$ 2.70</u>	<u>\$ 1.61</u>	<u>\$ 1.92</u>
<b>Diluted:</b>					
Continuing operations	\$ 1.39	\$ 1.03	\$ 2.42	\$ 1.35	\$ 1.61
Discontinued operations	0.31	0.31	0.27	0.26	0.30
<b>Diluted Earnings per Share</b>	<u>\$ 1.70</u>	<u>\$ 1.34</u>	<u>\$ 2.69</u>	<u>\$ 1.61</u>	<u>\$ 1.91</u>

**Kimberly-Clark Corporation and Subsidiaries**  
**Discontinued Operations of the IFP Business**  
**(Unaudited)**

(In millions)	Year Ended December 31	
	2024	2023
<b>Net Sales</b>	\$ 3,253	\$ 3,285
Cost of products sold	2,362	2,522
<b>Gross Profit</b>	891	763
Marketing, research and general expenses	381	346
Other (income) and expense, net	—	1
<b>Operating Profit</b>	510	416
Nonoperating expense	(1)	(1)
<b>Income from Discontinued Operations Before Income Taxes</b>	509	415
Provision for income taxes	(123)	(110)
<b>Income from Discontinued Operations, Net of Income Taxes</b>	\$ 386	\$ 305

(In millions)	Three Months Ended				
	March 31	December 31	September 30	June 30	March 31
<b>Net Sales</b>	\$ 786	\$ 824	\$ 808	\$ 798	\$ 823
Cost of products sold	562	594	588	582	598
<b>Gross Profit</b>	224	230	220	216	225
Marketing, research and general expenses	86	103	91	99	88
Other (income) and expense, net	—	(1)	1	1	(1)
<b>Operating Profit</b>	138	128	128	116	138
Nonoperating expense	(1)	(1)	—	—	—
<b>Income from Discontinued Operations Before Income Taxes</b>	137	127	128	116	138
Provision for income taxes	(34)	(24)	(36)	(27)	(36)
<b>Income from Discontinued Operations, Net of Income Taxes</b>	\$ 103	\$ 103	\$ 92	\$ 89	\$ 102

**Kimberly-Clark Corporation and Subsidiaries**  
**Segment Reporting**  
**Recast to Reflect the IFP Business as Discontinued Operations**  
**(Unaudited)**

(In millions)	Year Ended December 31	
	2024	2023
<b>Net Sales</b>		
NA	\$ 11,017	\$ 10,996
IPC	5,743	5,940
<b>Segment Net Sales<sup>(a)</sup></b>	<b>16,760</b>	<b>16,936</b>
Corporate & Other <sup>(b)</sup>	45	210
<b>Total Net Sales</b>	<b>\$ 16,805</b>	<b>\$ 17,146</b>

Operating Profit	Year Ended December 31	
	2024	2023
NA	\$ 2,542	\$ 2,514
IPC	826	673
<b>Segment Operating Profit<sup>(a)</sup></b>	<b>3,368</b>	<b>3,187</b>
Corporate & Other <sup>(b)</sup>	(668)	(1,259)
<b>Total Operating Profit</b>	<b>\$ 2,700</b>	<b>\$ 1,928</b>

(In millions)	Three Months Ended				
	March 31	December 31	September 30	June 30	March 31
	2025	2024	2024	2024	2024
<b>Net Sales</b>					
NA	\$ 2,668	\$ 2,723	\$ 2,735	\$ 2,783	\$ 2,776
IPC	1,386	1,381	1,409	1,427	1,526
<b>Segment Net Sales<sup>(a)</sup></b>	<b>4,054</b>	<b>4,104</b>	<b>4,144</b>	<b>4,210</b>	<b>4,302</b>
Corporate & Other <sup>(b)</sup>	—	—	—	21	24
<b>Total Net Sales</b>	<b>\$ 4,054</b>	<b>\$ 4,104</b>	<b>\$ 4,144</b>	<b>\$ 4,231</b>	<b>\$ 4,326</b>
<b>Operating Profit</b>					
NA	\$ 678	\$ 550	\$ 641	\$ 682	\$ 669
IPC	201	165	201	209	251
<b>Segment Operating Profit<sup>(a)</sup></b>	<b>879</b>	<b>715</b>	<b>842</b>	<b>891</b>	<b>920</b>
Corporate & Other <sup>(b)</sup>	(248)	(295)	184	(352)	(205)
<b>Total Operating Profit</b>	<b>\$ 631</b>	<b>\$ 420</b>	<b>\$ 1,026</b>	<b>\$ 539</b>	<b>\$ 715</b>

- (a) Segment Net Sales and Segment Operating Profit are non-GAAP financial measures as they exclude certain results included within Corporate & Other, as discussed below. Refer to "Summary of Non-GAAP Financial Measures" below for further discussion of how we utilize non-GAAP financial measures. As shown above, we have included a reconciliation to Total Net Sales and Total Operating Profit, as determined in accordance with GAAP.
- (b) Corporate & Other includes income and expense not associated with the ongoing operations of the segments, including certain operations of the former IFP segment that were divested prior to the IFP Transaction and costs previously allocated to the former IFP segment that aren't eligible to be reported as discontinued operations.

## SUMMARY OF NON-GAAP FINANCIAL MEASURES

The following provides the reconciliation of the non-GAAP financial measures summarized below to the most closely related GAAP measure. These measures include: Organic Sales Growth, Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate. These measures are provided on a continuing operations basis and exclude the impact of discontinued operations.

- Organic Sales Growth is defined as the change in Net Sales, as determined in accordance with U.S. GAAP, excluding the impacts of currency translation and divestitures and business exits.
- Adjusted Gross and Operating Profit, Adjusted Earnings per Share, and Adjusted Effective Tax Rate are defined as Gross Profit, Operating Profit, Diluted Earnings per Share, and Effective Tax Rate, respectively, as determined in accordance with U.S. GAAP, excluding the impacts of certain items that management believes do not reflect our underlying operations.

The income tax effect of these non-GAAP items on the Company's Adjusted Earnings per Share is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. The impact of these non-GAAP items on the Company's effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income from Continuing Operations Before Income Taxes and Equity Interests and Provision for income taxes.

We use these non-GAAP financial measures to assist in comparing our performance on a consistent basis for purposes of business decision making by removing the impact of certain items that we do not believe reflect our underlying and ongoing operations. We believe that presenting these non-GAAP financial measures is useful to investors because it (i) provides investors with meaningful supplemental information regarding financial performance by excluding certain items, (ii) permits investors to view performance using the same tools that management uses to budget, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating our results. We believe that the presentation of these non-GAAP financial measures, when considered together with the corresponding U.S. GAAP financial measures and the reconciliation to those measures, provides investors with additional understanding of the factors and trends affecting our business than could be obtained absent these disclosures.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. We compensate for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures. For further information about the non-GAAP adjustments included below, refer to our Annual Report on Form 10-K for the year ended December 31, 2024.

Summary of Non-GAAP financial measures:

	Year Ended December 31	
	2024	2023
<b>Adjusted Gross Profit</b>	\$ 6,433	\$ 6,284
<b>Adjusted Operating Profit</b>	2,727	2,542
<b>Adjusted Earnings per Share</b>	6.16	5.67
<b>Adjusted Effective Tax Rate</b>	22.7%	22.6%

	Three Months Ended					
	March 31	December 31	September 30	June 30	March 31	
	2025	2024	2024	2024	2024	
<b>Adjusted Gross Profit</b>	\$ 1,562	\$ 1,513	\$ 1,595	\$ 1,639	\$ 1,686	
<b>Adjusted Operating Profit</b>	706	556	682	729	760	
<b>Adjusted Earnings per Share</b>	1.62	1.19	1.56	1.70	1.71	
<b>Adjusted Effective Tax Rate</b>	20.7%	26.8%	21.5%	20.4%	23.1%	

The following tables provide a reconciliation of Organic Sales Growth from continuing operations:

Percent change vs. the prior year period	Year Ended December 31	
	2024	2023
<b>Net Sales Growth</b>	(2.0)	1.1
Currency Translation	4.2	3.0
Divestitures and Business Exits	1.6	0.7
<b>Organic Sales Growth<sup>(a)</sup></b>	<b>3.9</b>	<b>4.8</b>

Percent change vs. the prior year period	Three Months Ended				
	March 31	December 31	September 30	June 30	March 31
	2025	2024	2024	2024	2024
<b>Net Sales Growth</b>	(6.3)	(1.4)	(4.1)	(2.1)	(0.2)
Currency Translation	2.4	2.2	3.8	4.9	6.0
Divestitures and Business Exits	2.5	1.7	1.8	1.2	1.4
<b>Organic Sales Growth<sup>(a)</sup></b>	<b>(1.4)</b>	<b>2.5</b>	<b>1.5</b>	<b>4.0</b>	<b>7.3</b>

(a) Tables may not foot due to rounding.

The following tables provide a reconciliation of Adjusted Gross Profit from continuing operations:

	Year Ended December 31	
	2024	2023
<b>Gross Profit</b>	\$ 6,289	\$ 6,269
2024 Transformation Initiative	144	—
Sale of Brazil Tissue and Professional Business	—	15
<b>Adjusted Gross Profit</b>	<b>\$ 6,433</b>	<b>\$ 6,284</b>

	Three Months Ended				
	March 31	December 31	September 30	June 30	March 31
	2025	2024	2024	2024	2024
<b>Gross Profit</b>	\$ 1,509	\$ 1,445	\$ 1,564	\$ 1,594	\$ 1,686
2024 Transformation Initiative	53	68	31	45	—
<b>Adjusted Gross Profit</b>	<b>\$ 1,562</b>	<b>\$ 1,513</b>	<b>\$ 1,595</b>	<b>\$ 1,639</b>	<b>\$ 1,686</b>

The following tables provide a reconciliation of Adjusted Operating Profit from continuing operations:

	Year Ended December 31	
	2024	2023
<b>Operating Profit</b>	\$ 2,700	\$ 1,928
2024 Transformation Initiative	456	—
Sale of Personal Protective Equipment Business	(565)	—
Impairment of Intangible Assets	97	658
Legal Expense	39	—
Sale of Brazil Tissue and Professional Business	—	(44)
<b>Adjusted Operating Profit</b>	<b>\$ 2,727</b>	<b>\$ 2,542</b>

	Three Months Ended					March 31 2024
	March 31	December 31	September 30	June 30	March 31	
	2025	2024	2024	2024	2024	
<b>Operating Profit</b>	\$ 631	\$ 420	\$ 1,026	\$ 539	\$ 715	
2024 Transformation Initiative	75	97	124	190	45	
Sale of Personal Protective Equipment Business	—	—	(565)	—	—	
Impairment of Intangible Assets	—	—	97	—	—	
Legal Expense	—	39	—	—	—	
<b>Adjusted Operating Profit</b>	<b>\$ 706</b>	<b>\$ 556</b>	<b>\$ 682</b>	<b>\$ 729</b>	<b>\$ 760</b>	

The following tables provide a reconciliation of Adjusted Earnings per Share from continuing operations:

	Year Ended December 31	
	2024	2023
<b>Diluted Earnings per Share</b>	<b>\$ 6.41</b>	<b>\$ 4.31</b>
2024 Transformation Initiative	1.01	—
Sale of Personal Protective Equipment Business	(1.34)	—
Impairment of Intangible Assets	0.17	1.36
Legal Expense	0.11	—
Softex Tax Reserve Release	(0.20)	—
Sale of Brazil Tissue and Professional Business	—	(0.08)
Pension Settlements	—	0.08
<b>Adjusted Earnings per Share<sup>(a)</sup></b>	<b>\$ 6.16</b>	<b>\$ 5.67</b>

	Three Months Ended					March 31 2024
	March 31	December 31	September 30	June 30	March 31	
	2025	2024	2024	2024	2024	
<b>Diluted Earnings per Share</b>	<b>\$ 1.39</b>	<b>\$ 1.03</b>	<b>\$ 2.42</b>	<b>\$ 1.35</b>	<b>\$ 1.61</b>	
2024 Transformation Initiative	0.23	0.25	0.31	0.35	0.10	
Sale of Personal Protective Equipment Business	—	—	(1.34)	—	—	
Impairment of Intangible Assets	—	—	0.17	—	—	
Legal Expense	—	0.11	—	—	—	
Softex Tax Reserve Release	—	(0.20)	—	—	—	
<b>Adjusted Earnings per Share<sup>(a)</sup></b>	<b>\$ 1.62</b>	<b>\$ 1.19</b>	<b>\$ 1.56</b>	<b>\$ 1.70</b>	<b>\$ 1.71</b>	

- (a) The non-GAAP adjustments included above are presented net of tax. The income tax effect of these non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. Refer to the Adjusted Effective Tax Rate reconciliation below for the tax effect of these adjustments on the Company's reported Provision for income taxes.

The following tables provide a reconciliation of the continuing operations Adjusted Effective Tax Rate:

	Year Ended December 31			
	2024		2023	
	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes
<b>As Reported</b>	\$ 2,418	\$ (442)	\$ 1,606	\$ (343)
2024 Transformation Initiative	457	(118)	—	—
Sale of Personal Protective Equipment Business	(565)	112	—	—
Impairment of Intangible Assets	97	(40)	658	(175)
Legal Expense	39	(1)	—	—
Softex Tax Reserve Release	—	(67)	—	—
Sale of Brazil Tissue and Professional Business	—	—	(44)	18
Pension Settlements	—	—	35	(9)
<b>As Adjusted</b>	<b>\$ 2,446</b>	<b>\$ (556)</b>	<b>\$ 2,255</b>	<b>\$ (509)</b>

**Effective Tax Rate:**

As Reported	18.3%	21.4%
As Adjusted	22.7%	22.6%

	Three Months Ended March 31	
	2025	
	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes
<b>As Reported</b>	<b>\$ 557</b>	<b>\$ (131)</b>
2024 Transformation Initiative	77	—
<b>As Adjusted</b>	<b>\$ 634</b>	<b>\$ (131)</b>

**Effective Tax Rate:**

As Reported	23.5%
As Adjusted	20.7%

	Three Months Ended							
	December 31		September 30		June 30		March 31	
	2024		2024		2024		2024	
	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes	Income from Continuing Operations Before Income Taxes and Equity Interests	Provision for Income Taxes
<b>As Reported</b>	\$ 352	\$ (47)	\$ 962	\$ (187)	\$ 461	\$ (60)	\$ 643	\$ (148)
2024 Transformation Initiative	98	(16)	124	(18)	190	(73)	45	(11)
Sale of Personal Protective Equipment Business	—	—	(565)	112	—	—	—	—
Impairment of Intangible Assets	—	—	97	(40)	—	—	—	—
Legal Expense	39	(1)	—	—	—	—	—	—
Softex Tax Reserve Release	—	(67)	—	—	—	—	—	—
<b>As Adjusted</b>	<b>\$ 489</b>	<b>\$ (131)</b>	<b>\$ 618</b>	<b>\$ (133)</b>	<b>\$ 651</b>	<b>\$ (133)</b>	<b>\$ 688</b>	<b>\$ (159)</b>
<b>Effective Tax Rate:</b>								
As Reported	13.4%		19.4%		13.0%		23.0%	
As Adjusted	26.8%		21.5%		20.4%		23.1%	